Current trends in essential thrombocythaemia

Harrison, Claire

doi:10.1046/j.1365-2141.2002.03474.x

Cited by 49 publications

(26 citation statements)

References 116 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment with cytotoxic chemotherapy decreases the incidence of thrombohemorrhagic events but may increase the risk of hematological SPM [2] . The risk of SPM may be high in patients exposed to alkylating agents and radioactive phosphorus, more so when used in high doses [2,12,15,16] .…”

Section: Introductionmentioning

confidence: 99%

“…The thrombohemorrhagic events and second primary malignancy (SPM) are among the frequent causes of death in ET [1012] . ET may progress to other myeloid malignancies such as myelofibrosis, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) [2,12] . The probability of transformation to leukemia is 1%5% during the first decade but increases significantly in the subsequent decades [2,6] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Shrestha¹,

Giri²,

Pathak³

et al. 2016

WJCO

View full text Add to dashboard Cite

AIM:To determine the risk of second primary malignancy (SPM) and survival of patients with essential thrombocythemia (ET). METHODS:We identified all patients with ET diagnosed during 2001 to 2011 from the Surveillance, Epidemiology and End Results (SEER) 18 database. Actuarial and relative survival methods were used to calculate the survival statistics. We utilized the SEER 13 database to calculate SPM. We used multiple primary standardized incidence ratio (SIR) session of the SEER*Stat software (version 8.1.5) to calculate SIR and excess risk of SPM for ET patients. RESULTS:Age standardized five-year cause-specific survival was greater for patients < 50 years vs those ≥ 50 years (99.4% vs 93.5%, P < 0.01). Five-year cause- Shrestha R, Giri S, Pathak R, Bhatt VR. Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia. World J Clin Oncol

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Shrestha¹,

Giri²,

Pathak³

et al. 2016

WJCO

View full text Add to dashboard Cite

show abstract

“…ET is one of the cMPD according to the WHO classification and has the most favorable outcome comparing to other cMPD [15,16,17]. Although earlier analysis of actuarial survival among patients with ET indicated no significant decrease in their life expectancy, the more recent population-based Olmsted County Study suggested that survival among patients with ET was significantly worse than that among age- and sex-matched healthy control subjects [18].…”

Section: Introductionmentioning

confidence: 99%

Clinical Correlation of Bone Marrow Microvessel Density in Essential Thrombocythemia

Panteli

Ζαγοριανάκου²,

Agnantis³

et al. 2005

Acta Haematol

View full text Add to dashboard Cite

The aim of this study was to investigate the prognostic relevance of angiogenesis expressed as bone marrow microvessel density (MVD) in 40 patients with essential thrombocythemia (ET). Bone marrow MVD was visualized in paraffin tissue sections using immunohistochemical staining for CD34 protein. Increased MVD of bone marrow specimens was not significantly correlated with clinical (sex, age, microvascular disturbances, liver and spleen size, complications, treatment or no before biopsy), laboratory (peripheral blood count), bone marrow histopathological parameters (cellularity, megakaryocyte clumping and reticulin fibrosis) and overall survival. These preliminary findings suggest that angiogenesis has no prognostic value in patients with ET.

show abstract

“…1 Essential thrombocythemia is a diagnosis of exclusion that needs to deduct both reactive thrombocytosis and other myeloprolifeartive disorder. 2 Life expectancy in essential thrombocythemia is normal but mortality increases if associated comorbidities are present. 3 Rarely, some patient develops acute myeloid leukemia and myelofibrosis.…”

Section: Introductionmentioning

confidence: 99%

Essential thrombocythemia presenting as digital ischemia

Hasan

Rahim

Ahmed

et al. 2017

Bangabandhu Sheikh Mujib Medical University Journal

View full text Add to dashboard Cite

<p class="Abstract">Essential thrombocythemia is a myeloproliferative disease and is characterized by increased production of platelet and increased megakaryocytes in the bone marrow. Though platelets are high in number but may not function normally and can cause hyperviscosity syndrome and blockage of the blood vessels and other complications. Here, we report two cases of essential thrombocythemia, presented with pain in hands and feet and one with digital infarction. Both the patients had headache and vertigo.</p>

show abstract

Current trends in essential thrombocythaemia

Cited by 49 publications

References 116 publications

Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Clinical Correlation of Bone Marrow Microvessel Density in Essential Thrombocythemia

Essential thrombocythemia presenting as digital ischemia

Contact Info

Product

Resources

About